MX2023013849A - Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa. - Google Patents

Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa.

Info

Publication number
MX2023013849A
MX2023013849A MX2023013849A MX2023013849A MX2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A MX 2023013849 A MX2023013849 A MX 2023013849A
Authority
MX
Mexico
Prior art keywords
post
treatment
methods
autoimmune diabetes
infectious autoimmune
Prior art date
Application number
MX2023013849A
Other languages
English (en)
Spanish (es)
Inventor
Francisco Leon
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of MX2023013849A publication Critical patent/MX2023013849A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2023013849A 2021-05-24 2022-05-24 Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa. MX2023013849A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
MX2023013849A true MX2023013849A (es) 2023-12-08

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013849A MX2023013849A (es) 2021-05-24 2022-05-24 Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa.

Country Status (10)

Country Link
US (1) US20220372146A1 (https=)
EP (1) EP4347021A4 (https=)
JP (1) JP2024521164A (https=)
KR (1) KR20240023522A (https=)
CN (1) CN117794572A (https=)
AU (1) AU2022283272A1 (https=)
CA (1) CA3219473A1 (https=)
IL (1) IL308627A (https=)
MX (1) MX2023013849A (https=)
WO (1) WO2022251258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
IL298999A (en) * 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) * 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES

Also Published As

Publication number Publication date
CN117794572A (zh) 2024-03-29
EP4347021A4 (en) 2025-04-23
IL308627A (en) 2024-01-01
AU2022283272A1 (en) 2023-12-07
US20220372146A1 (en) 2022-11-24
EP4347021A1 (en) 2024-04-10
WO2022251258A1 (en) 2022-12-01
KR20240023522A (ko) 2024-02-22
JP2024521164A (ja) 2024-05-28
CA3219473A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
MX2023013851A (es) Metodos para el tratamiento de diabetes tipo 1.
MX2023013849A (es) Metodos para el tratamiento de diabetes autoinmunitaria post-infecciosa.
MX2021009622A (es) Metodos para tratar la colestasis.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
CL2024000466A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2022000143A (es) Metodos novedosos.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CL2025000279A1 (es) Arn para prevenir o tratar tuberculosis
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
AR122127A1 (es) VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
CL2024002764A1 (es) Tratamiento de neurofibromas plexiformes asociados a neurofibromatosis tipo 1 (nf1) en pacientes pediátricos con mirdametinib
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2025011577A (es) Metodos para la reduccion del uso de insulina exogena
CL2023003841A1 (es) Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
MX2019001412A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
MX2023011720A (es) Una composicion para su uso en el tratamiento de mhc-i-opatias.